Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 1, 2007, Pages 65-74

  Kim, Roy J ^a   Carlow, Dean C ^a   Rutstein, Jessica H ^b   Rutstein, Richard M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Adiponectin; Child; Growth; HIV; Lipids; Lipoatrophy; Lipodystrophy

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; CHILD; CHILD CARE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG USE; DYSLIPIDEMIA; FEMALE; FREQUENCY ANALYSIS; GENDER; GROWTH DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFECTION CONTROL; INFORMATION RETRIEVAL; LIPOATROPHY; MALE; MEDICAL RECORD; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; METABOLISM; PATHOPHYSIOLOGY;

ADIPONECTIN; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, HDL; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; GROWTH DISORDERS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE;

EID: 34047265158     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.1.65     Document Type: Article

References (54)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
2. Barbaro G, DiLorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, Barbarini G. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 2003; 25: 2405-2418.
3. Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet 1999; 353: 1243-1244.
4. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405-410.
5. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001; 27: 30-34.
6. Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, Allen HF. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 2003; 22: 463-465.
7. Leonard EF, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22: 77-84.
8. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, Levy-Marchal C. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123-2128.
9. Bitnun A, Sochett E, Dick PT, To T, Jefferies C, Babyn P, Forbes J, Read S, King SM. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005; 90: 168-174.
10. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003; 32: 482-489.
11. Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, di Natale B, Vigano A. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001; 15: 2415-2422.
12. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001; 7: 941-946.
13. Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, Nelson KW, Ballantyne CM. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004; 89: 2697-2703.
14. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
15. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002; 31: 514-520.
16. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active anti-retroviral therapy. J Clin Endocrinol Metab 2003; 88: 627-636.
17. Kamoda T, Saitoh H, Saito M, Sugiura M, Matsui A. Serum adiponectin concentrations in newborn infants in early postnatal life. Pediatr Res 2004; 56: 690-693.
18. Iniguez G, Soto N, Avila A, Salazar T, Ong K, Dunger D, Mericq V. Adiponectin levels in the first two years of life in a prospective cohort: relations with weight gain, leptin levels and insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 5500-5503.
19. Tsou PL, Jiang YD, Chang CC, Wei JN, Sung FC, Lin CC, Chiang CC, Tai TY, Chuang LM. Sex-related differences between adiponectin and insulin resistance in schoolchildren. Diabetes Care 2004; 27: 308-313.
20. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
21. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
22. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
23. Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, Girard PM, Levan P, Rozenbaum W, Lombes A, Capeau J, Bastard JP. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9: 555-564.
24. Lagathu C, Kim M, Maachi M, Vigouroux C, Cervera P, Capeau J, Caron M, Bastard JP. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005; 87: 65-71.
25. Lindegaard B, Hansen AB, Gerstoft J, Pedersen BK. High plasma level of interleukin-18 in HIV-infected subjects with lipodystrophy. J Acquir Immune Defic Syndr 2004; 36: 588-593.
26. Christeff N, Melchior JC, de Truchis P, Perronne C, Gougeon ML. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 2002; 32: 43-50.
27. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003; 321: 1-15.
28. Nystrom T, Nygren A, Sjoholm A. Increased levels of tumour necrosis factor-alpha in type 2 diabetic patients after myocardial infarction are related to endothelial dysfunction. Clin Sci (Lond) 2006; 110: 673-681.
29. Caldwell M, Oxtoby M, Simonds R, Rogers M. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43: 1-10.
30. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998; 101: 141-147.
31. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395-400.
32. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG; HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-735.
33. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwerski S, Yarchoan R, Zeichner S. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004; 114: e235-242.
34. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N, Houang M, Chevenne D, Hankard R, Bresson JL, Blanche S, Levy-Marchal C. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40: 161-168.
35. Verkauskiene R, Dollfus C, Levine M, Faye A, Deghmoun S, Houang M, Chevenne D, Bresson J-L, Blanche S, Levy-Marchal C. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr Res 2006; 60: 225-230.
36. Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E, Bluher M, Kiess W. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89: 4053-4061.
37. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4542-4548.
38. Hulthe J, Hulten LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1612-1614.
39. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 312-321.
40. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, Andersen O. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285: E1072-1080.
41. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamaki A, Nyman T, Vidal H, Hamsten A, Yki-Jarvinen H. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17: 1753-1762.
42. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P, Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-1031.
43. Lindegaard B, Hansen AB, Pilegaard H, Keller P, Gerstoft J, Pedersen BK. Adipose tissue expression of IL-18 and HIV-associated lipodystrophy. AIDS 2004; 18: 1956-1958.
44. Carey VJ, Yong FH, Frenkel LM, McKinney RE Jr. Pediatric AIDS prognosis using somatic growth velocity. AIDS 1998; 12: 1361-1369.
45. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immuno-deficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997; 16: 968-974.
46. van Rossum AM, Niesters HG, Geelen SP, Scherpbier HJ, Hartwig NG, Weemaes CM, Veerman AJ, Suur MH, de Graeff-Meeder ER, Slieker WA, Hop WC, Osterhaus AD, Burger DM, De Groot R. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 Infections. J Pediatr 2000; 136: 780-788.
47. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics 200 1; 107: E77.
48. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002; 109: E25.
49. Watson DC, Counts DR. Growth hormone deficiency in HIV-infected children following successful treatment with highly active antiretroviral therapy. J Pediatr 2004; 145: 549-551.
50. Weinberg GA, Jospe N. Growth hormone deficiency and HIV infection. J Pediatr 2005; 147: 559-560.
51. Vigano A, Mora S, Brambilla P, Schneider L, Merlo M, Monti LD, Manzoni P. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS 2003; 17: 1435-1441.
52. Rondanelli M, Caselli D, Arico M, Maccabruni A, Magnani B, Bacchella L, De Stefano A, Maghnie M, Solerte SB, Minoli L. Insulin-like growth factor I (IGF-1) and IGF-binding protein 3 response to growth hormone is impaired in HIV-infected children. AIDS Res Hum Retroviruses 2002; 18: 331-339.
53. Van Rossum AM, Gaakeer MI, Verweel S, Hartwig NG, Wolfs TF, Geelen SP, Lamberts SW, de Groot R. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J 2003; 22: 70-76.
54. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86: 504-510.